Cargando…
Personalized prediction of EGFR mutation-induced drug resistance in lung cancer
EGFR mutation-induced drug resistance has significantly impaired the potency of small molecule tyrosine kinase inhibitors in lung cancer treatment. Computational approaches can provide powerful and efficient techniques in the investigation of drug resistance. In our work, the EGFR mutation feature i...
Autores principales: | Wang, Debby D., Zhou, Weiqiang, Yan, Hong, Wong, Maria, Lee, Victor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790204/ https://www.ncbi.nlm.nih.gov/pubmed/24092472 http://dx.doi.org/10.1038/srep02855 |
Ejemplares similares
-
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments
por: Wang, Debby D., et al.
Publicado: (2015) -
Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations
por: Zhu, Mengxu, et al.
Publicado: (2021) -
Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma
por: Sun, Ruizhu, et al.
Publicado: (2022) -
Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics
por: Ma, Lichun, et al.
Publicado: (2016) -
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
por: Ma, Lichun, et al.
Publicado: (2015)